Catalog No.
YHF19803
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Asp28-Arg80
Predicted molecular weight
34.35 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P56856
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Claudin-18, CLDN18, UNQ778/PRO1572
Knockdown of Claudin-8 (CLDN8) Indicates a Link Between Breast Cancer Cell Sensitivity to Chemotherapeutics and Reveals a Potential Use of CLDN8 as a Molecular Diagnostic and Target for Therapy., PMID:40508219
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial., PMID:40460847
Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR-SCREEN-2 Study., PMID:40455642
Cleavage of CAD by caspase-3 determines the cancer cell fate during chemotherapy., PMID:40442064
Zolbetuximab-clzb: Targeting Claudin 18.2 in Advanced Gastric and Gastroesophageal Adenocarcinoma., PMID:40426305
Cellular therapies in sarcoma and other solid tumors., PMID:40423031
CLDN18.2 CAR-derived Extracellular Vesicle Immunotherapy Improves Outcome in Murine Pancreatic Cancer., PMID:40384272
Evaluation of tumor targets selected from public genomic databases for imaging of pancreatic ductal adenocarcinoma., PMID:40379788
Claudin 18.2 Expression in Gastric Tumors and Other Tumor Types With Gastric Epithelium-like Differentiation., PMID:40295026
Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell treatment resistance in advanced gastric cancer., PMID:40246985
Claudin 18.2: a promising actionable target in biliary tract cancers., PMID:40215597
Heterogeneity of predictive biomarker expression in gastric and esophago-gastric junction carcinoma with peritoneal dissemination., PMID:40205072
Discordance in Claudin 18.2 Expression Between Primary and Metastatic Lesions in Patients With Gastric Cancer., PMID:40200874
Targeted Radionuclide Therapy of CLDN18.2-Positive Gastric Cancer with [131I]I-Zolbetuximab: An In Vitro and In Vivo Study., PMID:40200396
Two cases of protein-losing enteropathy induced by zolbetuximab in patients with unresectable advanced gastric cancer., PMID:40194315
Claudin 18.2 expression profile in primary tumors and their ovarian metastases: implications for targeted therapy., PMID:40133876
Claudin18.2-positive gastric cancer-specific changes in neoadjuvant chemotherapy-driven immunosuppressive tumor microenvironment., PMID:40128286
Claudin 18 (43-14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for zolbetuximab therapy., PMID:40117781
A novel signature predicts prognosis in pancreatic cancer based on tumor membrane-associated genes., PMID:40066030
IDO1 inhibition enhances CLDN18.2-CAR-T cell therapy in gastrointestinal cancers by overcoming kynurenine-mediated metabolic suppression in the tumor microenvironment., PMID:40045363
A CLDN18.2-Targeted Nanoplatform Manipulates Magnetic Hyperthermia Spatiotemporally for Synergistic Immunotherapy in Gastric Cancer., PMID:40019387
Evaluating the pharmacokinetics of zolbetuximab in gastric adenocarcinoma., PMID:40015974
Identification of potential biomarkers for lung cancer using integrated bioinformatics and machine learning approaches., PMID:40014586
Claudin 18.2 Is Not a Promising Biomarker for Targeted Immunotherapy in Prostatic Cancers., PMID:40010986
The value of serum tumor-associated autoantibodies in screening and diagnosis of gastric cancer., PMID:39900126
Claudin 18.2 Immunohistochemistry Expression in Gastric Cancer: A Systematic Review., PMID:39894972
Cell-Based Therapies in GI Cancers: Current Landscape and Future Directions., PMID:39841955
Utility of 131I-HLX58-Der for the Precision Treatment: Evaluation of a Preclinical Radio-Antibody-Drug-Conjugate Approach in Mouse Models., PMID:39839455
Claudin 18.2 Expression in 1404 Digestive Tract Adenocarcinomas Including 1175 Colorectal Carcinomas: Distinct Colorectal Carcinoma Subtypes Are Claudin 18.2 Positive., PMID:39826799
The high efficacy of claudin18.2-targeted CAR-T cell therapy in advanced pancreatic cancer with an antibody-dependent safety strategy., PMID:39797399
Zolbetuximab for Unresectable and Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma: A Review of Literature., PMID:39759684
Exploring novel therapeutic targets in small bowel adenocarcinoma: insights from claudin 18.2, nectin-4, and HER3 expression analysis., PMID:39754977
Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights., PMID:39753814
Expression of claudin-18.2 in cholangiocarcinoma: a comprehensive immunohistochemical analysis from a German tertiary centre., PMID:39731204
Efficacy and Safety of Zolbetuximab in Gastric Cancer., PMID:39699854
[Claudin-18.2 and gastric cancer: from physiology to carcinogenesis]., PMID:39686903
Expression of therapy target molecules in esophagogastric junction and Barrett's adenocarcinoma., PMID:39663311
The small protein LINC01547-ORF inhibits colorectal cancer progression by regulating the CLDN18-FAK-AKT axis., PMID:39659940
Claudin-18 and Mutation Surrogate Immunohistochemistry in Gastric-type Endocervical Lesions and their Differential Diagnoses., PMID:39652450
[A New Molecular Targeted Agent for Gastric Cancer-The Anti-Claudin 18.2 Antibody, Zolbetuximab]., PMID:39648123
Emerging targets in gastric and pancreatic cancer: Focus on claudin 18.2., PMID:39637967
Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer., PMID:39615405
Relationship between [18F]FDG PET/CT findings and claudin 18.2 expression in metastatic gastric cancer., PMID:39572448
Survival outcomes of patients with gastric cancer treated with first-line nivolumab plus chemotherapy based on claudin 18.2 expression., PMID:39528778
[Claudine 18.2: A new therapeutic target in digestive cancers]., PMID:39516118
The role of CLDN18.2 in gastric cancer prognosis: a systematic review and meta-analysis., PMID:39461890
Preclinical Development of T Cells Engineered to Express a T-Cell Antigen Coupler Targeting Claudin 18.2-Positive Solid Tumors., PMID:39404622
Expression of claudin 18.2 in poorly cohesive carcinoma and its association with clinicopathologic parameters in East Asian patients., PMID:39368365
Emerging Claudin18.2-targeting Therapy for Systemic Treatment of Gastric Cancer: Seeking Nobility Amidst Danger., PMID:39364863
Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers., PMID:39321207
For research use only. Not for human or drug use.
